However, we now have evidence that constitutive NRF2 activation via mutations in KEAP1 or recurrent NFE2L2 exon 2 deletions can drive tumor proliferation and metastasis (Goldstein et al,2016; Rojo de la Vega et al,2018). Here, KEAP1 is linked to neoplasm.